Relapse into drug taking among addicts often depends on learned associations between drug-paired cues and the rewarding effects of these drugs, such as cocaine (COC). Memory for drug-paired cues resists extinction and contributes to the high rate of relapse; however, the molecular mechanisms underlying these associations are not understood. We show that COCconditioned place preference (CPP) activates ERK, CREB, Elk-1, and Fos in the nucleus accumbens core (AcbC) but not shell. Intra-AcbC infusions of U0126, an inhibitor of the ERK kinase MEK, prevent both the activation of ERK, CREB, Elk-1, and Fos and retrieval of COC-CPP. When tested again 24 hr or 14 days after intra-AcbC infusions of U0126 or another MEK inhibitor, PD98059, CPP retrieval and concomitant protein activation were significantly attenuated. Together, these findings indicate the necessity of the AcbC ERK signaling pathway for drug-paired contextual cue memories and suggest that these strong memories can become susceptible to disruption by therapeutic agents.
Introduction
Cocaine (COC) produces marked alterations in behavior and mood in humans. Repeated intake increases the likelihood of abuse of the drug, leading to the development of addiction. Relapse into drug seeking in addicts often depends on the association formed between drug-paired cues and the rewarding effects of the drug. A conditioned physiological response and feelings of intense craving can occur when abstinent drug abusers encounter cues predictive of drug availability (Childress et al., 1988) . Memory for these drugpaired cues is highly resistant to extinction and contributes to the high rate of relapse among addicts. One animal model often used to study this contextual cueelicited COC craving is conditioned place preference (CPP), in which rats learn to associate the rewarding effects of COC with the environmental context in which it is administered and later show a preference for that environment.
The neural circuitry of cue-elicited drug seeking involves several structures, including the basolateral amygdala complex (BLC), prelimbic cortex (PrL), and nucleus accumbens (Acb) (Weiss et ). These findings suggest that ERK, CREB, and Elk-1 may be candidates for involvement in the storage and retrieval of memories for COCassociated contextual cues.
In this study, we trained animals in a CPP apparatus to associate one chamber with COC. Animals were later tested for their place preference in a drug-free state and sacrificed to assess pERK, pCREB, and pElk-1 activation using immunocytochemistry (ICC) and Western blot analysis. To assess ERK's involvement in retrieval of the CPP memory, another group of animals received intra-AcbC infusions of U0126, an inhibitor of MEK, 30 min before CPP testing. These animals were then perfused to assess pERK, pCREB, pElk-1, and Fos levels within the AcbC. To test for an enduring effect of acute ERK inhibition, we assessed the effects of U0126 or another MEK inhibitor, PD98059, on reconsolidation of memory for the drug-paired environment. The reconsolidation hypothesis states that memories, when retrieved, can become labile and susceptible to disruption. Animals were given either pre-or posttest intra-AcbC infusions of U0126 and then tested again 24 hr or 14 days later. pERK, pCREB, pElk-1, and Fos levels were again assessed within the AcbC. The results of these experiments demonstrate several ways in which the AcbC ERK pathway is important in memory for COC-associated contextual cues. First, animals expressing COC-CPP showed activation of the ERK pathway in the Acb core, but not shell. Second, inhibition of AcbC ERK phosphorylation blocked the retrieval of COC-CPP. Third, when AcbC ERK phosphorylation was blocked immediately after retrieval, both preference for the COC-associated chamber and retrieval-dependent protein activation were disrupted for at least 2 weeks. These findings demonstrate the necessity of the AcbC ERK signaling pathway for drugpaired contextual cue memory and prompt the therapeutically significant conclusion that these strong memories can become susceptible to disruption.
Results

Acb ERK, CREB, and Elk-1 Activation following COC-CPP Expression
Following CPP behavioral conditioning, drug-paired animals showed an increase from baseline ("initial test") in the amount of time spent in the COC-paired compartment, whereas drug-unpaired animals did not ( Figure 1A ). There was a significant group by test interaction [F(1, 17) = 8.62; p < 0.01], and drug-paired but not unpaired controls spent significantly more time in the COC-paired compartment during the final, compared to the initial test (Wilcoxon tests, drug-paired: z = −2.31, p < 0.05; unpaired: z = −0.97, p > 0.05). These findings demonstrate the development of a preference for the environment previously paired with COC.
Following CPP testing, pERK, pCREB, and pElk-1 immunoreactivity was examined in the AcbC and AcbSh ( Figure 1B Taken together, these results establish that CPP expression induces phosphorylation of ERK, CREB and Elk-1 and that this activation is specific to the core of the Acb. Because only the AcbC showed increased levels of all three phosphoproteins, subsequent experiments targeted the ERK signaling pathway in this brain area.
Effect of MEK Inhibition within the AcbC on Retrieval of COC-CPP
To assess ERK's involvement in memory retrieval, another group of animals was trained on CPP and received intra-AcbC infusions of the MEK inhibitor U0126 30 min before CPP testing. To examine the anatomic specificity of the intraAcbC infusions, the numbers of pERK-ir cells were also counted in the AcbSh of veh-and U0126-infused animals following retrieval. In contrast to the U0126-induced decrease in pERK-ir in the AcbC described above, no difference in pERK-ir was observed in the AcbSh of vehand U0126-infused animals [Veh: 13.17 ± 3.6; U0126: 16.26 ± 6.9; F(31) = 2.42; p > 0.05]. These results suggest that there was little, if any, spread of the MEK inhibitor beyond the AcbC.
Effect of MEK Inhibition within the AcbC on Reconsolidation of COC-CPP
To test for a lasting effect of acute ERK inhibition, we assessed its effect on reconsolidation of memory for the drug-paired environment 24 hr later. For this experiment, all animals received COC pairings during CPP Figure 6A ). While the CPP memory of the Vehposttest group was still intact on test day 2, the animals of the PD98059-posttest group failed to express a preference (t 20 = −4.45, p < 0.001; Figure 6A ).
These results demonstrate that both MEK inhibitors, U0126 and PD98059, are able to impair memory 24 hr after their intra-AcbC infusion if the infusion is coupled with a retrieval test on day 1.
Because of evidence suggesting that drug-induced interference with reconsolidation of fear conditioning may fade at longer drug-retest intervals (Lattal and Abel, 2004), we repeated the experiment but delayed the second CPP test for 14 days. The first CPP retrieval test (test day 1) was immediately followed by intraAcbC infusions of U0126 (U0126-posttest) or veh (Vehposttest). The animals were returned to their home cages for 14 days before being given a second test (test day 15). Numbers of AcbC pERK-, pCREB-, pElk-1-, and Fos-ir cells were also counted following the day 15 test. These findings suggest that (1) retrieved memories, not simply established memories, are susceptible to disruption by MEK inhibition when it is active during or immediately after retrieval, and (2) this effect lasts at least 2 weeks.
Effect of MEK Inhibition within the AcbC on pERK, pCREB, pElk-1, and Fos Levels following Test of Reconsolidation
Animals that received MEK inhibitor infusions at the time of memory retrieval on test day 1 (U0126-pretest, U0126-posttest, and PD98059-posttest) showed a significant attenuation of pERK, pCREB, pElk-1, and Fosir relative to all other groups when assayed after CPP testing on test day 2 or 15.
For the results depicted in Figure 5C (U0126 infusions, test day 2), a significant interaction between drug treatment and infusion time was observed for all four proteins These results reveal that the MEK inhibitor's action on this signaling pathway cannot be explained by an acute pharmacological effect; instead, it results from antagonism of a memory-dependent cascade. The retrieval-dependent suppression of the ERK signaling cascade during subsequent memory tests further supports the view that activation of the AcbC ERK signaling cascade underlies cue-elicited COC seeking. Furthermore, any contribution of the ERK signaling pathway in AcbC nonneuronal cells to the effects observed in these experiments appears to be minor.
Discussion
Recent research has attempted to link molecular aspects of the neural mechanisms underlying the behavioral effects of repeated drug administration and those responsible for more traditional forms of learning and memory. The present findings advance our current knowledge by demonstrating that inhibition of one intracellular signaling cascade during or immediately after retrieval interferes with a classically conditioned memory for drug-paired contextual cues.
Rats were trained to associate COC treatment with distinctive environmental cues. Following expression of COC-CPP in a drug-free state, ERK and two downstream transcription factors, CREB and Elk-1, were activated, with significantly increased pERK, pCREB, and pElk-1 levels in the AcbC, but not AcbSh. We previously . Because ERK activation was inhibited in our MEK inhibitor-infused animals, the interpretation that extinction is accelerated in these animals would assume that extinction learning is ERK independent. Yet, the extinction of fear conditioning has been shown to be ERK dependent (Cammarota et al., 2004) . In addition, it might be argued that infusion of U0126 reduces the time spent in the COC-paired chamber by inducing a conditioned place aversion in these animals. However, the U0126-infused animals exhibited an equivalent number of entries into the drug-paired compartment at the initial test and test day 2, suggesting the U0126 infusion on test day 1 did not cause these animals to avoid the COC-paired compartment. Also, these animals did not spend less time in the COCpaired compartment relative to the initial test ( Figure  6A ), which would have been expected if an aversion had developed.
While CPP is an excellent model of cue-elicited drug seeking because of its simplicity, the rapidity with which drug-paired associations develop, and the resistance of those memories to extinction, certain limitations exist. For instance, with CPP the amount and pattern of drug administration is set by the experimenter, rather than the animal. An important future extension of the current findings will be to replicate them in another model of cue-elicited drug seeking, such as cue-elicited reinstatement of self-administration.
The AcbC Contributes to COC-CPP Memory
The Acb is recognized as important for motivation directed at drug seeking by integrating pertinent information from the prefrontal cortex and amygdala and relaying it to motor output structures. Exposure to COC-paired cues causes an elevation in Acb neuron firing rates ( Beyond supporting a role for the AcbC in motivation for drug-paired contextual cues, our findings indicate a role for this brain region in memory for these associations. Of special interest is the involvement of AcbC ERK in both COC-CPP retrieval and reconsolidation. Blockade of the ERK signaling pathway via MEK inhibition appears to have two effects within the AcbC. First, the MEK inhibitor acutely interferes with COC-CPP retrieval, preventing cue-elicited drug seeking. Similar findings have been reported for MEK inhibition of methamphetamine-CPP recall (Mizoguchi et al., 2004) . Second, and more surprisingly, MEK inhibition within the AcbC has an enduring effect by blocking reconsolidation of memories for the COC-paired environment, an effect that lasts for at least 2 weeks. Importantly, the blockade of a place preference only occurred when the MEK inhibitor was combined with a COC-CPP test. This finding indicates (1) that the lack of a place preference on test day 2 cannot be attributed to residual MEK inhibitor still present in the animals' brains, as U0126-infused animals not tested on test day 1 (U0126-no test group) showed normal CPP on test day 2 and (2) that the U0126 and PD98059 infusions had a lasting amnestic effect (at least 2 weeks postinfusion) only when the MEK inhibition coincided with memory retrieval.
The discovery of an important role for the ERK signaling pathway in both retrieval and reconsolidation is of interest. Recently, Winters and Bussey (2005) found that retrieval and consolidation of object recognition are similarly impaired by transient inactivation of AMPA receptors in the perirhinal cortex, but reconsolidation was not investigated. To our knowledge, the current study is the first to identify a molecular mechanism that blocks both retrieval and reconsolidation of any type of memory. While much remains to be understood concerning the cellular processes underlying the effects of ERK in drug-stimulus associations and other types of learning and memory, the present findings offer hope for treating cue-elicited relapse in addicts. It is widely accepted that memories for drug-associated stimuli, which are strong and resistant to extinction, are responsible for much of the relapse seen in addicts. The present findings suggest that these highly resistant memories may again be made labile and thus susceptible to disruption by pharmacological or other neurobiological interventions, providing opportunities for new therapies.
Role of ERK in Retrieval of COC-CPP Memory
Experimental Procedures Animals
All animals were individually housed on a 12 hr light/dark cycle with ad libitum access to food and water. The housing conditions and care of the animals were consistent with those specified in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources on Life Science, National Research Council, 1996). All procedures were performed during the light part of the diurnal cycle. Male Sprague-Dawley rats, weighing 250-275 g were handled for 5 days prior to behavioral conditioning. Rats to receive cannula implants weighed 275-300 g and were handled for 2 days prior to surgery.
Place Preference Apparatus
Conditioning took place in a three-chamber apparatus consisting of two larger compartments (29 cm × 25 cm) separated by a smaller compartment (11 cm × 25 cm). The two larger compartments had different visual, tactile, and olfactory cues (see Miller and Marshall, 2004 for details).
Control Environment
In addition to placing animals in the compartments of the conditioning chamber, animals were placed in an alternate environment for control purposes as described below. The control environment consisted of a clear plastic cage (27 cm × 48 cm), distinct from the home cage, located in a room independent of both the CPP apparatus and holding rooms.
Cannula Implantation
Rats undergoing surgery were anesthetized with equithesin and secured in a Kopf stereotaxic apparatus. Bilateral stainless steel guide cannulae (26G; Plastics One, Roanoke, VA) were aimed at the AcbC (AP: +1.6 mm relative to bregma; ML: ±2.3 mm; DV: −7.6 mm, from skull; Paxinos and Watson, 1998). Clearance through the guide cannulae was maintained with 33G obturators (Plastics One) cut to project 1 mm beyond the tip of the guide. Animals were habituated to dummy cannula removal and given 5 days of recovery and handling before the start of behavioral conditioning. 
Drugs
U0126 (Promega
Behavioral Conditioning
Baseline preferences were assessed by placing the animals in the center compartment of the place preference apparatus and allowing free access to all compartments for 15 min. Time spent in each compartment was recorded. Because a Wilcoxon signed ranks test revealed no significant overall preference for either large compartment initially, we arbitrarily paired the COC injections with the checkered compartment. Conditioning took place over the next 9 days. The animals were divided into a drug-paired and a drugunpaired group, such that each group had an equal mean initial time spent in each compartment. The drug-unpaired group served as a control for history of COC administration. These animals received amounts of COC-HCl (10 mg/kg, i.p.; Sigma) equal to those administered to the drug-paired animals, but given in the control environment and sal (1 ml/kg, i.p.) prior to placement in each of the CPP compartments. Removable partitions were put in place for the conditioning days, confining animals to a specific compartment for 30 min. A counterbalanced design was used so that half of the drug-paired animals were given COC prior to placement in the checkered compartment on the first day, and half received sal prior to placement in the white compartment (for further details, see Miller and Marshall, 2004) . Forty-eight hours after the last conditioning session, preference was assessed as previously described. A difference score was calculated by subtracting the time spent in the COC-paired compartment at baseline from time spent during the final test. Animals to receive intra-AcbC infusions were divided into three groups (U0126, veh, or sal infusion) after initial testing. Because a Wilcoxon signed ranks test revealed no significant overall preference for either compartment initially, we arbitrarily chose to pair the COC injections with the white compartment. For these experiments, the control environment was not used. The behavioral conditioning consisted of three COC pairings, alternated with three sal pairings over 6 days. Thirty minutes prior to or immediately after the final place preference testing, animals were given an intraAcbC infusion of 0.5 l of sal, veh, or U0126 ( In a similar experiment, animals to receive intra-AcbC infusions were divided into two groups (U0126 or veh infusion) after initial testing. Immediately after the final place preference testing, animals were given an intra-AcbC infusion of 0.5 l of veh or U0126 (1 g) over 2 min and returned to their home cage. Fourteen days later, test day 15, these same animals were again CPP tested. ) for approximately 2 min, after which they were stored at −80°C. AcbC and AcbSh (+1.6 mm relative to bregma; Paxinos and Watson, 1998) punches were obtained with a 1 mm punch tool (Zivic Laboratories, Inc., Pittsburgh, PA) from 1 mm thick sections taken on a sliding freezing microtome (see Figure 2B ).
Tissue Preparation for Western Blotting
Tissue Preparation for ICC
Half of the rats that did not receive intra-AcbC infusions were euthanized 15 min after completion of the final CPP test, while rats that received intra-AcbC infusions were euthanized 90 min after completion of their respective final CPP test. All animals were deeply anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and transcardially perfused with ice-cold 0.1 M phosphate-buffered sal (PBS) (pH 7.4), followed by ice-cold 4% paraformaldehyde in PBS (pH 7.4), with 0.1 mM NaF. The brains were removed, post fixed overnight at 4°C, and then transferred to 30% sucrose for 48 hr at 4°C. Coronal sections (40 m) were collected at the level corresponding to Acb using a freezing microtome. One set of tissue from rats that received intra-AcbC infusions was stained with cresyl violet to verify the location of the infusion needle tips.
Western Blotting
Punches were sonicated in 60 l of ice-cold lysis buffer (150 mM NaCl, 50 mM NaF, 10 mM β-glycerol, 20 mM HEPES [pH 7.4], 1% Triton X-100, and 1× Halt protease inhibitor cocktail, EDTA-free). Laemmli buffer was added to the homogenates, and the samples were boiled at 95°C for 10 min. Homogenates containing 5 g of protein from either the AcbC or AcbSh were electrophoresed on 4%-20% SDS-polyacrylamide gels and blotted to 0.2 m nitrocellulose membranes. Western blots were first incubated with antibodies to pERK, pCREB, and pElk-1. Blots intended for pERK and pElk-1 antibodies were blocked in Tris-buffered sal with Tween (TBST; 100 mM Tris-HCl [pH 7.6], 150 mM NaCl, and 0.1% Tween 20) and 5% milk. Blots intended for the pCREB antibody were blocked in TBST with 5% bovine serum albumin (BSA; Sigma). Blots were then incubated with an anti-phospho-p44/42 MAPK (pERK) rabbit polyclonal antibody (1:20,000; #9101, Cell Signaling, Beverly, MA), anti-phospho-CREB rabbit polyclonal antibody (1:1000; #9191, Cell Signaling), or anti-phospho-Elk-1 mouse monoclonal antibody (1:2000; #sc-8406, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight at 4°C (pERK, pCREB) or at room temperature (RT) overnight (pElk-1). Blots were then incubated with anti-rabbit (pERK and pCREB) or anti-mouse (pElk-1) secondary antibody conjugated to horseradish peroxidase (HRP; 1:10,000; Vector Laboratories; Burlingame, CA) and developed using enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent substrate; Pierce, Rockford, IL). All blots were then incubated in anti-cyclophilin rabbit polyclonal antibody (1:20,000; #07-313, Upstate, Lake Placid, NY) with TBST and 5% milk overnight at 4°C. Blots were then incubated with anti-rabbit secondary antibody conjugated to HRP (1:10,000) and developed using enhanced chemiluminescence. All blots were then incubated in Restore Western Blot Stripping Buffer (Pierce) for 15 min at RT to remove the antibodies directed at the phosphoproteins and allow for binding of antibodies directed at the nonactive form of the proteins. Blots were incubated in anti-MAPK (ERK) rabbit polyclonal antibody (1:10,000; #9102, Cell Signaling), anti-CREB rabbit polyclonal antibody (1:1000; #9192, Cell Signaling), or anti-Elk-1 rabbit polyclonal antibody (1:1000; #sc-355, Santa Cruz Biotechnology, Inc.) with TBST and 5% milk (ERK and Elk-1) or TBS (no Tween) and 5% BSA (CREB) overnight at 4°C (pERK, pCREB) or at RT overnight (pElk-1). Blots were then incubated with anti-rabbit secondary antibody conjugated to HRP (1:10,000) and developed using enhanced chemiluminescence.
ICC
Serial coronal sections through Acb were processed for pERK, pElk-1, and pCREB-ir from animals tested for CPP expression and pERK, pElk-1, pCREB, and Fos-ir from animals given intra-AcbC infusions and tested for CPP retrieval or reconsolidation.
Sections processed for pERK were rinsed in 0.3% H pCREB ICC was performed as described for pERK with the following exceptions. All solutions were made in 0.1 M PBS with 0.1 mM NaF. Sections were incubated for 24 hr at RT with anti-phospho-CREB rabbit polyclonal antibody (1:5000; #06-519, Upstate).
Fos ICC was performed as described for pERK with the following exceptions. All solutions for Fos ICC were made in 0.1 M PBS. Sections were incubated for 48 hr at 4°C with anti-Fos rabbit polyclonal antibody (1:15,000; PC-38, Oncogene Science, Cambridge, MA).
To evaluate the neuronal-specific pERK antibody labeling, a subset of AcbC sections from ten animals infused with the veh for PD98059 were processed for pERK and NeuN double immunofluorescence. Sections were treated as described above for pERK-ir, except that the antibody concentration was 1:200 and the sections were incubated at RT overnight. Instead of ABC and Ni-DAB, the sections were incubated with avidin-bound Fluorescein (20 g/ml; Vector) for 2 hr. The tissue was then incubated in PBS containing 3% BSA for 1 hr, followed by incubation overnight at RT with antineuronal nuclei (NeuN) mouse monoclonal antibody (1:500; #MAB377, Chemicon). The sections were incubated in avidinbound Rhodamine (20 g/ml; Vector) for 2 hr. Sections were rinsed in Tris, mounted, dried overnight, dipped in xylene, and coverslipped using Fluoromount.
Western Blot Analysis
Western blots were developed in the linear range used for densitometry. Densitometry was conducted using MCID image analysis software. To assess changes in the activation of ERK1, ERK2, CREB, and Elk-1, activated kinase levels were normalized both to levels of the respective kinases as well as to cyclophilin, which was used as a loading control protein. To analyze the extent of pERK-ir overlap with the neuronal marker NeuN within the AcbC, sections were digitized under 100× magnification. Images of pERK-ir AcbC cells were collected using filters for Fluorescein (Leica L5; Ex = 495-500 nm). Images of NeuNir AcbC cells were collected using filters for Rhodamine (Leica Y3; Ex = 550-560 nm). pERK-ir neurons were then assessed for their overlap with NeuN-ir.
Immunoreactivity Quantification
Statistical Analysis
The experimenter was blind to treatment groups when taking all measures. For experiments conducted on cannulated rats, only animals in which the tips of the infusion needles were located within the AcbC were included in the analyses (Figure 3) . CPP, ICC, and Western blot data derived from comparing drugpaired and unpaired groups (Figures 1A and 1B; Figures 2A and  2B) were analyzed by mixed factor ANOVA, with drug pairing as a between-subjects factor and test session or Acb regions as a within-subjects factor. Data from ICC or Western blotting of each phosphoprotein were analyzed separately. When significant group by test or region interactions occurred, specific comparisons between initial and final CPP scores were made using a Wilcoxon signed ranks test, while specific comparisons between drug-paired and unpaired groups were made using Student's t tests.
Effects of U0126 on CPP retrieval ( Figure 4A ) were subjected to the same mixed-factor ANOVA, in which infusion (veh versus U0126) was a between-subjects factor and test session was a within-subjects factor. Separate one-way ANOVAs were used to compare these two groups for CPP difference scores, locomotor measures, and immunoreactivity ( Figures 4B and 4C) . Effects of U0126 on CPP reconsolidation and accompanying immunoreactivity ( Figures 5A and 5B) were analyzed by 2 × 2 (for test day 1 CPP scores) or 3 × 2 (for test day 2 CPP scores and ICCs) ANOVAs. In each analysis, intra-AcbC drug treatment (veh versus U0126) and infusion time were between-subject factors. Significant interactions between drug treatment and infusion time were observed for each of the 3 × 2 ANOVAs.
Orthogonal comparisons were then conducted on the significant interactions observed in the 3 × 2 ANOVAs to test whether (1) the "no test" groups differed from the "pretest" and "posttest" groups, and (2) the "pretest" and "posttest" groups differed. Selected specific group comparisons were made using Student's t tests.
CPP data for the PD98059 and U0126 15 day experiments (Figures 6A and 7A) were also analyzed using two-way factorial ANOVAs, in which intra-AcbC infusion type (veh versus MEK inhibitor) was a between-subjects factor and test day was a within-subjects factor. Specific comparisons between MEK inhibitor and vehinfused groups were made using Student's t tests for each of the test days. ICC data from each region of those experiments (Figures 6B and 7B) were analyzed by one-way ANOVAs.
Bonferroni corrections were used for all Student's t tests and one-way ANOVAs.
